Literature DB >> 26319061

Persistence of measles antibodies, following changes in the recommended age for the second dose of MMR-vaccine in Portugal.

Guilherme Gonçalves1, João Frade2, Carla Nunes3, João Rodrigo Mesquita4, Maria São José Nascimento5.   

Abstract

In populations vaccinated with two doses of combined measles-mumps-rubella vaccine (MMR), the serum levels of antibodies against measles depend on the vaccination schedule, time elapsed from the last dose and the area-specific epidemiological situation. Variables measuring "schedule" are age at first and second doses of MMR and intervals derived from that. Changes in vaccination schedules have been made in Portugal. The specific objectives of this study were to measure the association between those potential determinants and the concentration of measles-specific IgG antibodies, after the second dose of MMR. Convenience samples of three Portuguese birth cohorts were selected for this study (41, 66 and 60 born, respectively, in 2001-2003, 1990-1993 and 1994-1995). Geometric mean concentrations (GMC) for measles IgG were, respectively, 934, 251 and 144mIU/ml; p<0.001). Anti-measles-IgG serum concentration decreased with time since last vaccination (waning immunity) and was not influenced by any other component of vaccination schedule, namely age at vaccination with the second dose of MMR. Waning levels of measles antibodies have been observed elsewhere but not as fast as it was observed in Portuguese birth cohorts in this study. Changes in the vaccination schedules might have to be considered in the future.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibodies; Immunisation; Measles; Measles–mumps–rubella (MMR) vaccine; Vaccination schedule

Mesh:

Substances:

Year:  2015        PMID: 26319061     DOI: 10.1016/j.vaccine.2015.08.057

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Dynamic Features of Herd Immunity: Similarities in Age-Specific Anti-Measles Seroprevalence Data between Two Countries of Different Epidemiological History.

Authors:  Katalin Böröcz; Senka Samardžić; Ines Drenjančević; Ákos Markovics; Tímea Berki; Péter Németh
Journal:  J Clin Med       Date:  2022-02-21       Impact factor: 4.241

2.  Persistence of rubella and mumps antibodies, following changes in the recommended age for the second dose of MMR vaccine in Portugal.

Authors:  G Gonçalves; J Frade; M S J Nascimento; J R Mesquita; C Nunes
Journal:  Epidemiol Infect       Date:  2016-08-04       Impact factor: 4.434

Review 3.  Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses.

Authors:  Mark K Slifka; Ian J Amanna
Journal:  Front Immunol       Date:  2019-05-01       Impact factor: 8.786

4.  Seroprevalence to Measles Virus after Vaccination or Natural Infection in an Adult Population, in Italy.

Authors:  Gabriele Anichini; Claudia Gandolfo; Simonetta Fabrizi; Giovan Battista Miceli; Chiara Terrosi; Gianni Gori Savellini; Shibily Prathyumnan; Daniela Orsi; Giuseppe Battista; Maria Grazia Cusi
Journal:  Vaccines (Basel)       Date:  2020-02-03

Review 5.  Eradication of measles: remaining challenges.

Authors:  Heidemarie Holzmann; Hartmut Hengel; Matthias Tenbusch; H W Doerr
Journal:  Med Microbiol Immunol       Date:  2016-03-02       Impact factor: 3.402

6.  High Concentrations of Measles Neutralizing Antibodies and High-Avidity Measles IgG Accurately Identify Measles Reinfection Cases.

Authors:  Sun B Sowers; Jennifer S Rota; Carole J Hickman; Sara Mercader; Susan Redd; Rebecca J McNall; Nobia Williams; Marcia McGrew; M Laura Walls; Paul A Rota; William J Bellini
Journal:  Clin Vaccine Immunol       Date:  2016-08-05

7.  A Serosurvey Identifying Vulnerability to Measles in Health Care Workers. A Hospital-Based Prospective Seroprevalence Study.

Authors:  Jana Malinová; Marek Petráš; Alexander M Čelko
Journal:  Int J Environ Res Public Health       Date:  2020-06-12       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.